Breaking News
0

The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals And Prudential Financial

By Zacks Investment ResearchStock MarketsSep 16, 2019 10:14PM ET
www.investing.com/analysis/the-zacks-analyst-blog-highlights-celgene-sinopec-hsbc-vertex-pharmaceuticals-and-prudential-financial-200465383
The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals And Prudential Financial
By Zacks Investment Research   |  Sep 16, 2019 10:14PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

For Immediate Release

Chicago, IL – September 17, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Celgene (NASDAQ:CELG) , Sinopec (NYSE:SNP) , HSBC Holdings (NYSE:HSBC) , Vertex Pharmaceuticals (NASDAQ:VRTX) and Prudential Financial (NYSE:PRU) .

Here are highlights from Monday’s Analyst Blog:

Top Stock Reports for Celgene, Sinopec and HSBC

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Celgene, Sinopec and HSBC Holdings. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Celgene’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past three months (1.2% vs. -4.3%). The Zacks analyst thinks that Celgene’s lead drug, Revlimid, continues to drive revenues on label expansions and market share gains.

Robust performance of psoriasis drug, Otezla, is also boosting Celgene’s performance. Investors are focusing on the company’s merger with large-cap pharma Bristol-Myers for a whopping $74 billion.

Per the terms, Celgene shareholders will receive $50 plus one share of Bristol-Myers and one tradeable Contingent Value Right, which will entitle the holder to receive a cash payment of $9.00 upon the receipt of FDA approval for three candidates — ozanimod, liso-cel and bb2121. The merger was initially opposed but was eventually given a green signal.

Shares of Sinopec have lost 26.4% in the past six months, underperforming the Zacks Integrated Oil industry’s fall of 18.3%. The Zacks analyst believes that the company has made major progress in identifying attractive and economically viable oil and natural gas reserves.

A huge scale of prospective reserves was discovered in a number of prolific natural gas basins like Sichuan and Ordos. The discoveries will help Sinopec capitalize on mounting clean energy demand as China is transitioning from coal to natural gas for electricity generations. However, China’s bleak economic outlook will continue to hurt the firm’s refining business.

In fact, soft refining margin primarily led the company to report dismal second-quarter 2019 earnings. Moreover, the firm’s cash flow declined 54% year over year in the first half of 2019, reflecting weak operations.

HSBC’s shares have lost 4.8% year to date, underperforming the Zacks Foreign Banks industry’s rise of 2.9% over the same period.

The Zacks analyst believes that the company’s initiatives to improve market share in the U.K. and China are likely to lead to an increase in expenses and hurt bottom-line growth. These efforts will support financials over the long term. Also, initiatives to strengthen digital capabilities globally, improve operating efficiency and open 50 new retail banking branches in the United States will go a long way in supporting profits.

Its steady capital deployments are impressive, reflecting a strong balance sheet position, and will enhance shareholder value. Nevertheless, disappointing economic growth in Europe and weak loan demand are likely to hurt revenue growth to some extent. Additionally, uncertainty related to the implication of Brexit on its financials remains a major near-term concern.

Other noteworthy reports we are featuring today include Vertex Pharmaceuticals and Prudential Financial.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”

Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.

See them now >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.



China Petroleum & Chemical Corporation (SNP): Free Stock Analysis Report

HSBC Holdings plc (HSBC): Free Stock Analysis Report

Prudential Financial, Inc. (PRU): Free Stock Analysis Report

Celgene Corporation (CELG): Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

Original post

Zacks Investment Research
The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals And Prudential Financial
 
The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals And Prudential Financial

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email